Our group’s clinical and translational research focuses on characterization of the central nervous system in HIV-infected patients in an effort to understand and treat the processes underlying damage to the nervous system by HIV, as well as establishment and reduction of potential central nervous system reservoirs for infection.
Our current program employs a multidisciplinary approach to patient-oriented research in neuro-HIV, through active collaborations with researchers in immunology, radiology, neuropsychology, virology, and molecular biomarkers. We apply these methods to novel studies of patients that may inform about neuroprotection and neuropathogenesis in HIV, including individuals with acute or early HIV infection, elite controllers who maintain undetectable viral loads in the absence of antiretroviral therapy, and patients at different stages of treatment with antiretroviral therapy. We are also performing clinical studies aimed to examine and/or reduce early establishment of central nervous system reservoirs for HIV infection.
Our studies focus on subjects recruited in urban centers in the US and other international sites including Bangkok, Thailand. Broader involvement with the design and implementation of multicenter studies relevant to neuro-HIV is facilitated by Dr. Spudich’s leadership position within the international AIDS Clinical Trials Group (ACTG), facilitated by an affiliation with the Cornell AIDS Clinical Trials Unit.
- Young AC, Yiannoutsos CT, Hegde M, Lee E, Peterson J, Walter R, Price RW, Meyerhoff DJ, Spudich S. Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection. Neurology. 2014 Sep 26.
- Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. Peluso MJ, Meyerhoff DJ, Price RW, Peterson J, Lee E, Young AC, Walter R, Fuchs D, Brew BJ, Cinque P, R
- Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, Boschini A, Gisslén M, Angoff N, Price RW, C
- Schnell G, Joseph S, Spudich S, Price RW, and Swanstrom R. HIV-1 Replication in the Central Nervous System Occurs in Two Distinct Cell Types. PloS Pathogens, 2011 Oct;7(10):e1002286.
- Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, Brew B, Fuchs D, Tambussi G, Cinque P, Hecht FM, and Price RW. Central Nervous System Immune Activation Characterizes Primary HIV-1 Infection Even in Subjects with Minimal Cerebrospinal Fluid Viral Burde
- Schnell G, Price RW, Swanstrom R, and Spudich S. Compartmentalization and Clonal Amplification of HIV-1 Variants in the Cerebrospinal Fluid during Primary Infection. Journal of Virology, 2010 84(5):2395-407.
- Probasco J, Deeks SG, Lee E, Hoh R, Price RW, Spudich S. Cerebrospinal Fluid in HIV-1 Systemic Viral Controllers: Absence of HIV-1 RNA and Intrathecal Inflammation. AIDS, 2010 24(7): 1001-5.